18:53 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

Cel-Sci Corp. (NYSE-M:CVM) said FDA lifted a clinical hold on the Phase III IT-MATTERS trial of Multikine leukocyte interleukin injection to treat squamous cell carcinoma of the head and neck (SCCHN). The open-label, international trial...
00:18 , May 19, 2017 |  BC Week In Review  |  Clinical News

Lorediplon meets in Phase II insomnia trial

In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint in a Phase II trial to treat insomnia. Specifically, low- and high-dose lorediplon significantly reduced mean Wake After...
00:59 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

PeproStat: Ph II started

Ergomed began a double-blind, placebo-controlled, European Phase IIb trial to evaluate topical PeproStat in about 120 patients undergoing liver, soft tissue, vascular or spinal surgery. Ergomed plc (LSE:ERGO), Guilford, U.K.  Product: PeproStat   Business: Hematology ...
07:00 , Oct 31, 2016 |  BC Extra  |  Company News

Management tracks

Rainer Boehm is retiring as chief commercial and medical affairs officer at the Novartis Pharma AG division of Novartis AG (NYSE:NVS; SIX:NOVN). Dhaval Patel is also retiring as European head of Novartis Institutes for BioMedical...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Multikine leukocyte interleukin injection: Phase III hold

Cel-Sci said it received verbal notice from FDA that the agency placed a clinical hold on an open-label, international Phase III trial comparing Multikine plus standard of care (SOC) vs. SOC alone. Cel-Sci said patients...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Lorediplon: Completed Phase IIa enrollment

Ergomed completed enrollment of >=130 adult insomniacs in a double-blind, placebo-controlled, crossover, international Phase IIa trial comparing 5 and 10 mg oral lorediplon vs. zolpidem. Ferrer is conducting the trial in collaboration with CRO Ergomed...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Financial News

Ergomed completes placing

Ergomed plc (LSE:ERGO), Guilford, U.K.   Business: Supply/Service   Date completed: 2016-05-24   Type: Placing   Raised: L9.2 million ($13.4 million)   Shares: 6.6 million   Price: 140p   Shares after offering: 39.7 million  ...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Ergomed proposes placing

Ergomed plc (LSE:ERGO), Guilford, U.K.   Business: Supply/Service   Date announced: 2016-05-04   Type: Placing   To be raised: L9 million ($12.9 million)   Shares: 6.4 million   Price: 140p   Shares outstanding prior: 28.8...
07:00 , May 9, 2016 |  BC Week In Review  |  Company News

Haemostatix, Ergomed deal

Ergomed proposed to acquire Haemostatix for L8 million ($11.7 million) up front. Haemostatix shareholders are also eligible for L4 million ($5.9 million) for the start of a Phase III trial and up to L16 million...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Financial News

LAM Therapeutics completes venture financing

LAM Therapeutics , Guilford, Conn.   Business: Pulmonary, Cancer   Date completed: 2016-02-03   Type: Venture financing   Raised: $40 million  ...